Improvement of primary Sjögren's syndrome salivary gland function by Xinfeng capsule and its effect on EGR1-STAT3 signaling pathway.

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Pharmacy and Pharmacology Pub Date : 2024-10-14 DOI:10.1093/jpp/rgae121

Ling Zhu, Beijia Wang, Pingping Li, Gangli Cheng, Su Bu, Sijie Bian, Xiaoting Qiu, Jian Liu, Xingxing Huo

{"title":"Improvement of primary Sjögren's syndrome salivary gland function by Xinfeng capsule and its effect on EGR1-STAT3 signaling pathway.","authors":"Ling Zhu, Beijia Wang, Pingping Li, Gangli Cheng, Su Bu, Sijie Bian, Xiaoting Qiu, Jian Liu, Xingxing Huo","doi":"10.1093/jpp/rgae121","DOIUrl":null,"url":null,"abstract":"Objectives: The study was aimed to investigate the effects of Xinfeng capsule (XFC) on tissue morphology, and gland function of the salivary gland (SG) in a primary Sjögren's syndrome (pSS) mouse model.Methods: An animal model of pSS was established by inducing SG protein in C57BL/6 mice. SG tissues were collected for tissue sequencing and subsequent experiments to detect the expression of cholinergic receptor muscarinic 3(M3R), early growth response factor 1 (EGR1) and target genes in the SG before and after XFC intervention, with in vitro validation.Results: Downstream targets of the EGR1 gene were predicted and analyzed using data analysis. EGR1 showed high expression and was selected for subsequent experiments. Administration of XFC significantly increased saliva production (P < 0.001) and reduced the extent of lymphatic infiltration observed in SG. Furthermore, the expression of EGR1 was increased in the model group with statistical significance in contrast with the control group but decreased after administration of XFC (P < 0.05). Data analysis predicted the downstream target of EGR1 as signal transducer and activator of transcription 3 (STAT3), which was validated in SG tissues of mice (P < .05).Conclusions: XFC demonstrated a significant improvement in the salivary secretion function of the SG in pSS mice. EGR1 can serve as a biomarker and therapeutic target for pSS.","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpp/rgae121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The study was aimed to investigate the effects of Xinfeng capsule (XFC) on tissue morphology, and gland function of the salivary gland (SG) in a primary Sjögren's syndrome (pSS) mouse model.

Methods: An animal model of pSS was established by inducing SG protein in C57BL/6 mice. SG tissues were collected for tissue sequencing and subsequent experiments to detect the expression of cholinergic receptor muscarinic 3(M3R), early growth response factor 1 (EGR1) and target genes in the SG before and after XFC intervention, with in vitro validation.

Results: Downstream targets of the EGR1 gene were predicted and analyzed using data analysis. EGR1 showed high expression and was selected for subsequent experiments. Administration of XFC significantly increased saliva production (P < 0.001) and reduced the extent of lymphatic infiltration observed in SG. Furthermore, the expression of EGR1 was increased in the model group with statistical significance in contrast with the control group but decreased after administration of XFC (P < 0.05). Data analysis predicted the downstream target of EGR1 as signal transducer and activator of transcription 3 (STAT3), which was validated in SG tissues of mice (P < .05).

Conclusions: XFC demonstrated a significant improvement in the salivary secretion function of the SG in pSS mice. EGR1 can serve as a biomarker and therapeutic target for pSS.

查看原文本刊更多论文

新风胶囊对原发性Sjögren综合征唾液腺功能的改善及其对EGR1-STAT3信号通路的影响

研究目的本研究旨在探讨新风胶囊（XFC）对原发性斯约格伦综合征（pSS）小鼠模型唾液腺（SG）组织形态和腺体功能的影响：方法：通过诱导 C57BL/6 小鼠体内的 SG 蛋白，建立 pSS 动物模型。方法：通过诱导 C57BL/6 小鼠的 SG 蛋白建立 pSS 动物模型，收集 SG 组织进行组织测序和后续实验，检测 XFC 干预前后 SG 中胆碱能受体 muscarinic 3(M3R)、早期生长应答因子 1 (EGR1) 和靶基因的表达，并进行体外验证：结果：利用数据分析预测并分析了 EGR1 基因的下游靶标。EGR1 表现出高表达，被选中进行后续实验。给予 XFC 能明显增加唾液分泌量（P < 0.001），并降低 SG 中观察到的淋巴浸润程度。此外，与对照组相比，模型组中 EGR1 的表达增加，具有统计学意义，但在给予 XFC 后则有所下降（P < 0.05）。数据分析预测 EGR1 的下游靶标为信号转导和转录激活因子 3（STAT3），这在小鼠的 SG 组织中得到了验证（P < .05）：结论：XFC 能明显改善 pSS 小鼠 SG 的唾液分泌功能。EGR1 可作为 pSS 的生物标记物和治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmacy and Pharmacology 医学-药学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： JPP keeps pace with new research on how drug action may be optimized by new technologies, and attention is given to understanding and improving drug interactions in the body. At the same time, the journal maintains its established and well-respected core strengths in areas such as pharmaceutics and drug delivery, experimental and clinical pharmacology, biopharmaceutics and drug disposition, and drugs from natural sources. JPP publishes at least one special issue on a topical theme each year.